centerforbiosimilars3h
Real-World UK, Ireland Study Confirms Long-Term Efficacy of SB5 in Psoriasis
SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.
centerforbiosimilars6h
FDA Reviews Golimumab Biosimilar, Samsung Biologics Hits Record Sales, Japan Approves Stelara Biosimilar
The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...
centerforbiosimilars19h
Prateek Yadav, MPTh, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1d
Gary Fanjiang, MD, MBA, MS
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1d
Courtney Flaherty
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars1d
Amanda Forys, MSPH
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Long-Term Data Support Use of Eculizumab Biosimilar as Soliris Alternative in PNH
Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...
centerforbiosimilars2d
Robert Rifkin, MD, FACP
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Christina Corridon, MPH, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars2d
Mike Gladstone
The Top 5 Biosimilar Articles for the Week of December 2 ...
centerforbiosimilars3d
Switching From Ustekinumab to Biosimilar SB17 Maintains Efficacy, Safety in Patients With Psoriasis
Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...
centerforbiosimilars3d
Jeff Baldetti, MBA
The Top 5 Biosimilar Articles for the Week of December 2 ...